Paul Korner

Dr. Korner has 21 years of pharmaceutical and biotech industry experience, having served in senior Clinical Development and Medical Affairs leadership positions within organizations such as Ferring Pharmaceuticals, Ardelyx Inc., Sarepta Therapeutics and Axovant Gene Therapies. He has been responsible for multiple INDs/CTAs and more than 50 clinical trials (phase 1-4), leading to marketing authorization/approvals of 10 products including VYONDYS 53® (golodirsen), NOCDURNA® (desmopressin), PREPOPIK® (sodium picosulfate), EUFLEXXA® (1% sodium hyaluronate), and YAZ® (EE/drospiranone).  

Dr. Korner has experience across novel pathways including gene therapy, vaccines, small molecules, peptides, and biologics across all development phases and multiple therapeutic areas including rare disease, CNS, women’s health, gastroenterology, nephrology, musculoskeletal/inflammation/orthopedics, and urology. He also serves on the Accreditation Council for Medical Affairs Scientific Advisory Board, and CEO of Korner BioPharma Advisors, LLC, providing strategic and operational clinical consulting services to small to biotech companies. Over the course of his career, he has authored forty-nine publications across multiple disease states. 

Dr. Korner is a board-certified obstetrician and gynecologist who was in private practice in Glencoe Illinois and Riverdale Georgia prior to joining industry in 1998. He received his B.S. in Biology from the University of Illinois (Champaign/Urbana), M.D. from Loyola University, Stritch School of Medicine in Maywood Illinois. He also holds an M.B.A. from the Michael J. Coles College of Business at Kennesaw State University in Georgia.